Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01246375
First received: November 21, 2010
Last updated: November 24, 2010
Last verified: November 2010
  Purpose

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.


Condition Intervention
Osteoporosis
Device: Dual energy X-ray absorptiometry

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Diagnosis of Osteoporosis [ Time Frame: 3 month ] [ Designated as safety issue: No ]
  • Diagnosis of Osteoporosis [ Time Frame: 3 ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: December 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Dual energy X-ray absorptiometry
    Device which measures bone density
  Eligibility

Ages Eligible for Study:   60 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Man at the minimum age of 60 years.
  2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
  3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

  1. Usage of systemic steroids more than once during the 12 months prior to the study.
  2. Usage of systemic steroids during the month prior to the study.
  3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01246375

Contacts
Contact: Eitan Segal, B.Sc 97236947507 eitansegal2@gmail.com

Locations
Israel
Tel Aviv medical center Not yet recruiting
Tel Aviv, Israel
Contact: Eitan segal, B.Sc    97236947507    eitansegal2@gmail.com   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Yehuda Schwartz, M.D Tel Aviv Medical Center
  More Information

No publications provided

Responsible Party: Dr. Yehuda Schwartz, Tel Aviv medical center
ClinicalTrials.gov Identifier: NCT01246375     History of Changes
Other Study ID Numbers: TASMC-10-SY-454-CTIL
Study First Received: November 21, 2010
Last Updated: November 24, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on September 16, 2014